39 related articles for article (PubMed ID: 34060284)
1. CytoLyt fixation impedes insulinoma-associated protein 1 (INSM1) immunoreactivity compared to formalin fixation.
Garlin-Politis M; Upadhyay Baskota S; Picon S; Collins N; Virk RK; Cimic A; Yousefi E; Gonzalez A
J Am Soc Cytopathol; 2024; 13(3):213-218. PubMed ID: 38575468
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemistry in the pathologic diagnosis and management of thyroid neoplasms.
Crescenzi A; Baloch Z
Front Endocrinol (Lausanne); 2023; 14():1198099. PubMed ID: 37324272
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Utility of INSM1 in Medullary Thyroid Carcinoma.
Seok JY; Kang M; De Peralta-Venturina M; Fan X
Int J Surg Pathol; 2021 Sep; 29(6):615-626. PubMed ID: 33650906
[TBL] [Abstract][Full Text] [Related]
4. Insulinoma-associated protein 1 (INSM-1) expression in medullary thyroid carcinoma FNA: a multi-institutional study.
Maleki Z; Abram M; Dell'Aquila M; Kilic I; Lu R; Musarra T; Barkan G; Rajakorpi E; Rossi ED; Kholová I
J Am Soc Cytopathol; 2020; 9(3):185-190. PubMed ID: 32197966
[TBL] [Abstract][Full Text] [Related]
5. Insulinoma-associated protein 1 immunostaining for various types of neuroendocrine tumors on FNA smears.
Hou T; Gan Q; Joseph CT; Sun X; Gong Y
Cancer Cytopathol; 2020 Oct; 128(10):725-732. PubMed ID: 32573984
[TBL] [Abstract][Full Text] [Related]
6. SDH-B, INSM1, and GATA3 expression in cauda equina neuroendocrine tumors: report on 21 cases from a North indian tertiary care center.
Sood R; Chatterjee D; Bhardwaj S; Singla N; Ahuja C; Radotra B
Hum Pathol; 2023 Jul; 137():18-24. PubMed ID: 37100233
[TBL] [Abstract][Full Text] [Related]
7. Relevance of immunocytochemistry on thin-layer cytology in thyroid lesions suspicious for medullary carcinoma: a case-control study.
Rossi ED; Raffaelli M; Mulè A; Zannoni GF; Pontecorvi A; Santeusanio G; Minimo C; Fadda G
Appl Immunohistochem Mol Morphol; 2008 Dec; 16(6):548-53. PubMed ID: 18685492
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic utility of INSM1 and GATA3 in discriminating problematic medullary thyroid carcinoma, thyroid and parathyroid lesions.
Adel Hakim S; Mohamed Abd Raboh N
Pol J Pathol; 2021; 72(1):11-22. PubMed ID: 34060284
[TBL] [Abstract][Full Text] [Related]
9. Paraganglioma-like medullary thyroid carcinoma: A case report and literature review.
Hou Y; He X; Chute DJ
Diagn Cytopathol; 2020 Jun; 48(6):559-563. PubMed ID: 32125784
[TBL] [Abstract][Full Text] [Related]
10. Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.
Gambardella C; Offi C; Clarizia G; Romano RM; Cozzolino I; Montella M; Di Crescenzo RM; Mascolo M; Cangiano A; Di Martino S; Candela G; Docimo G
BMC Endocr Disord; 2019 Oct; 19(1):103. PubMed ID: 31619220
[TBL] [Abstract][Full Text] [Related]
11. Serum calcitonin negative mixed medullary-follicular carcinoma initially diagnosed as medullary thyroid carcinoma by fine-needle aspiration cytology: A case report and review of the literatures.
Liu Y; Yuan L; Yang D; Jin Y
Diagn Cytopathol; 2018 Aug; 46(8):690-693. PubMed ID: 29524315
[TBL] [Abstract][Full Text] [Related]
12. Clinical challenges with calcitonin-negative medullary thyroid carcinoma.
Samà MT; Rossetto Giaccherino R; Gallo M; Felicetti F; Maletta F; Bonelli N; Piovesan A; Palestini N; Ghigo E; Arvat E
J Cancer Res Clin Oncol; 2016 Sep; 142(9):2023-9. PubMed ID: 27125958
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
